Literature DB >> 2521315

Multiple sclerosis: possible immunological mechanisms.

H F McFarland1, S Dhib-Jalbut.   

Abstract

Multiple sclerosis is the principal demyelinating disease of the central nervous system. Although the prevalence of the disease is moderately low, averaging about 40 cases per 100,000 people in high risk areas, it is a particularly devastating disease. It primarily affects young adults, is chronic, and has an unpredictable course. Most discouraging, the cause of the disease is not known and an effective treatment has not been identified. Recently, however, research has yielded some important findings concerning the etiology of MS. Much evidence now points to an immunological process as one of the major elements in the disease. It is also likely that an environmental influence, possibly an infectious process, may contribute to the disease. Finally, it is now certain that genetic makeup influences susceptibility to the disease. At present, the strongest evidence is for a polygenic effect, not the effect of a single gene or gene locus. This review will examine some of the possible immunologically mediated disease processes that could be involved in MS, especially those that could account for a role for infectious and genetic factors in the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521315      PMCID: PMC7133204          DOI: 10.1016/0090-1229(89)90116-5

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  41 in total

1.  Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS.

Authors:  S Gartner; P Markovits; D M Markovitz; R F Betts; M Popovic
Journal:  JAMA       Date:  1986-11-07       Impact factor: 56.272

2.  Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis.

Authors:  U Jahnke; E H Fischer; E C Alvord
Journal:  Science       Date:  1985-07-19       Impact factor: 47.728

3.  Astrocytes present myelin basic protein to encephalitogenic T-cell lines.

Authors:  A Fontana; W Fierz; H Wekerle
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

4.  Oligoclonal banding in MS.

Authors:  G C Ebers
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

5.  Viral particles induce Ia antigen expression on astrocytes.

Authors:  P T Massa; R Dörries; V ter Meulen
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

6.  Augmentation of immune-mediated demyelination by lipid haptens.

Authors:  C S Raine; U Traugott; M Farooq; M B Bornstein; W T Norton
Journal:  Lab Invest       Date:  1981-08       Impact factor: 5.662

7.  Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs.

Authors:  R J Clatch; H L Lipton; S D Miller
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

8.  Induction of autoimmune reactions to myelin basic protein in measles virus encephalitis in Lewis rats.

Authors:  U G Liebert; C Linington; V ter Meulen
Journal:  J Neuroimmunol       Date:  1988-01       Impact factor: 3.478

9.  Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition.

Authors:  S S Zamvil; P A Nelson; D J Mitchell; R L Knobler; R B Fritz; L Steinman
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Adoptive transfer of EAE-like lesions from rats with coronavirus-induced demyelinating encephalomyelitis.

Authors:  R Watanabe; H Wege; V ter Meulen
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

View more
  4 in total

Review 1.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Aaron Boster; Mary Pat Bartoszek; Colleen O'Connell; David Pitt; Michael Racke
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 3.  Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

Authors:  P Guinot
Journal:  Clin Rev Allergy       Date:  1994

4.  Microglial cells qualify as the stimulators of unprimed CD4+ and CD8+ T lymphocytes in the central nervous system.

Authors:  E Cash; O Rott
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.